Srivastava Swayam Prakash, Kopasz-Gemmen Olivia, Thurman Aaron, Rajendran Barani Kumar, Selvam M Masilamani, Kumar Sandeep, Srivastava Rohit, Suresh M Xavier, Kumari Reena, Goodwin Julie E, Inoki Ken
Life Sciences Institute, University of Michigan, Ann Arbor, MI, United States.
Department of Pediatrics, Yale University School of Medicine, New Haven, CT, United States.
Front Pharmacol. 2025 Apr 1;16:1563047. doi: 10.3389/fphar.2025.1563047. eCollection 2025.
Oxidation and reduction are vital for keeping life through several prime mechanisms, including respiration, metabolism, and other energy supplies. Mitochondria are considered the cell's powerhouse and use nutrients to produce redox potential and generate ATP and HO through the process of oxidative phosphorylation by operating electron transfer and proton pumping. Simultaneously, mitochondria also produce oxygen free radicals, called superoxide (O ), non-enzymatically, which interacts with other moieties and generate reactive oxygen species (ROS), such as hydrogen peroxide (HO), peroxynitrite (ONOO-), and hydroxyl radical (OH). These reactive oxygen species modify nucleic acids, proteins, and carbohydrates and ultimately cause damage to organs. The nutrient-sensing kinases, such as AMPK and mTOR, function as a key regulator of cellular ROS levels, as loss of AMPK or aberrant activation of mTOR signaling causes ROS production and compromises the cell's oxidant status, resulting in various cellular injuries. The increased ROS not only directly damages DNA, proteins, and lipids but also alters cellular signaling pathways, such as the activation of MAPK or PI3K, the accumulation of HIF-1α in the nucleus, and NFkB-mediated transcription of pro-inflammatory cytokines. These factors cause mesenchymal activation in renal endothelial cells. Here, we discuss the biology of redox signaling that underlies the pathophysiology of diabetic renal endothelial cells.
Front Pharmacol. 2025-4-1
Am J Physiol Regul Integr Comp Physiol. 2004-11
J Biol Chem. 2018-9-19
Res Rep Health Eff Inst. 2023-12
Handb Exp Pharmacol. 2021
Methods Mol Biol. 2017
Cell Death Dis. 2024-8-1
Int J Mol Sci. 2024-7-10
Biomed Pharmacother. 2024-6
Front Endocrinol (Lausanne). 2024-4-5
Signal Transduct Target Ther. 2024-3-22
Signal Transduct Target Ther. 2023-10-2
Mol Cancer. 2023-8-18